Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, China; Institute of Immunology PLA & Department of Immunology, College of Basic Medicine, Army Medical University (Third Military Medical University), Chongqing 400038, China; Department of Immunology, College of Basic Medicine, Weifang Medical University, Weifang 261053, China.
Institute of Immunology PLA & Department of Immunology, College of Basic Medicine, Army Medical University (Third Military Medical University), Chongqing 400038, China.
J Proteomics. 2023 Jan 6;270:104746. doi: 10.1016/j.jprot.2022.104746. Epub 2022 Oct 7.
The peptides repertoire presented to CD8 T cells by major histocompatibility complex (MHC) class I molecules is referred to as the MHC I-associated peptidome (MIP), which regulates thymus development, peripheral survival and function during lifetime of CD8 T cells. Type 1 diabetes (T1D) is an organ-specific autoimmune disease caused by pancreatic β cells destruction mediated primarily by autoreactive CD8 T cells. Non-obese diabetic (NOD) mouse is an important animal model of T1D. Here, we deeply analyzed the MIP derived from NOD mice thymus and pancreas, and demonstrated that the thymus MIP source proteins partially shared with the MIP source proteins derived from NOD mice pancreas and β cell line. One H-2Kd restricted peptide SLC35B1 which was shared by MIP derived from both NOD mice pancreatic tissues and islet β-cell line, but absent in MIP from NOD thymus tissues, showed ability to stimulate IFN-γ secretion and proliferation of NOD mice splenic CD8 T cells. The global view of the MHC I-associated self-peptides repertoire in the thymus and pancreas of NOD mice may serve as a biological reference to identify potential autoantigens targeted by autoreactive CD8 T cells in T1D. Data are available via ProteomeXchange with identifier PXD031966. SIGNIFICANCE: The peptides repertoire presented to CD8 T cells by major histocompatibility complex (MHC) class I molecules is referred to as the MHC I-associated peptidome (MIP). The MIP presented by thymic antigen presenting cells (APCs) is crucial for shaping CD8 T cell repertoire and self-tolerance, while the MIP presented by peripheral tissues and organs is not only involved in maintaining periphery CD8 T cell survival and homeostasis, but also mediates immune surveillance and autoimmune responses of CD8 T cells under pathological conditions. Type 1 diabetes (T1D) is an organ-specific autoimmune disease caused by the destruction of pancreatic β cells, mediated primarily by autoreactive CD8 T cells. Non-obese diabetic (NOD) mouse is one of important animal models of spontaneous autoimmune diabetes that shares several key features with human T1D. The global view of the MHC I-associated self-peptides repertoire in the thymus and pancreas of NOD mice may serve as a good biological reference to identify potential autoantigens targeted by autoreactive CD8 T cells in T1D. It has great significance for further clarifying the immune recognition and effect mechanism of autoreactive CD8 T cells in the pathogenesis of T1D, and then developing antigen-specific immune intervention strategies.
主要组织相容性复合物 (MHC) Ⅰ类分子呈递的肽段被称为 MHCⅠ相关肽组 (MIP),它调节胸腺发育、外周 CD8 T 细胞的存活和功能。1 型糖尿病 (T1D) 是一种由胰腺β细胞破坏引起的器官特异性自身免疫性疾病,主要由自身反应性 CD8 T 细胞介导。非肥胖型糖尿病 (NOD) 小鼠是 T1D 的重要动物模型。在这里,我们深入分析了 NOD 小鼠胸腺和胰腺的 MIP,结果表明,胸腺 MIP 的来源蛋白部分与来源于 NOD 小鼠胰腺和β细胞系的 MIP 的来源蛋白共享。一个 H-2Kd 限制性肽 SLC35B1 存在于来源于 NOD 小鼠胰腺组织和胰岛β细胞系的 MIP 中,但不存在于来源于 NOD 小鼠胸腺组织的 MIP 中,它能够刺激 NOD 小鼠脾 CD8 T 细胞分泌 IFN-γ并增殖。NOD 小鼠胸腺和胰腺 MHCⅠ相关自身肽组的整体视图可作为识别 T1D 中自身反应性 CD8 T 细胞靶向的潜在自身抗原的生物学参考。数据可通过 ProteomeXchange 以标识符 PXD031966 获取。
意义:主要组织相容性复合物 (MHC) Ⅰ类分子呈递的肽段被称为 MHCⅠ相关肽组 (MIP)。胸腺抗原呈递细胞 (APC) 呈递的 MIP 对于塑造 CD8 T 细胞 repertoire 和自身耐受性至关重要,而外周组织和器官呈递的 MIP 不仅参与维持外周 CD8 T 细胞的存活和稳态,而且介导病理条件下 CD8 T 细胞的免疫监视和自身免疫反应。1 型糖尿病 (T1D) 是一种由胰腺β细胞破坏引起的器官特异性自身免疫性疾病,主要由自身反应性 CD8 T 细胞介导。非肥胖型糖尿病 (NOD) 小鼠是自发性自身免疫性糖尿病的重要动物模型之一,与人类 T1D 具有几个关键特征。NOD 小鼠胸腺和胰腺的 MHCⅠ相关自身肽组的全貌可作为识别 T1D 中自身反应性 CD8 T 细胞靶向的潜在自身抗原的良好生物学参考。它对于进一步阐明 T1D 发病机制中自身反应性 CD8 T 细胞的免疫识别和作用机制,进而开发抗原特异性免疫干预策略具有重要意义。
Cell Mol Immunol. 2024-6
Novartis Found Symp. 2008